- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Gabapentin increasingly linked to overdose deaths: CDC report
![Gabapentin increasingly linked to overdose deaths: CDC report Gabapentin increasingly linked to overdose deaths: CDC report](https://medicaldialogues.in/h-upload/2022/07/01/750x450_179763-gabapentins.webp)
USA: Gabapentin was detected in almost 1 in 10 US overdose deaths between 2019 and 2020, according to a report from the CDC's Division of Overdose Prevention. The report further stated that the medical examiner or coroner ruled the drug was a cause of death in about half of the cases.
Gabapentin was approved by the US Food and Drug Administration (FDA) for the treatment of seizures and pain associated with shingles. The prescription rate doubled from about 13 to 27 per 1000 insurance beneficiaries between 2009 and 2016 due to the growing off-label prescribing of gabapentin for nerve pain and other conditions. As a matter of fact, gabapentin had become the seventh most prescribed drug in the US by 2019.
Sometimes, gabapentin is used to amplify the effects of illicit opioids. The FDA issued a warning in late 2019 that gabapentin may cause serious breathing difficulties when used with drugs that depress the central nervous system, such as anti-anxiety medications, opioids, and antidepressants.
Now, the report from the State Unintentional Drug Overdose Reporting System from 23 states and the District of Columbia indicates that the role of gabapentin in the US overdose deaths may be growing. Overall, toxicology tests revealed gabapentin's role in 5687 overdose deaths between 2019 and 2020—about 10% of all cases with test results available. Overdose deaths in which gabapentin was detected doubled from 449 in the first quarter of 2019 to 959 in the second quarter of 2020.
The proportion of these cases that medical examiners ruled was caused by the drug increased from 50% in early 2019 to 55% by late 2020. About 90% of these cases also involved opioids, primarily illicitly manufactured fentanyl. About 83% of deaths caused by gabapentin occurred among White adults aged 35 to 54 years.
"Persons who use illicit opioids with gabapentin should be educated about the increased risk for respiratory depression and death," the authors wrote.
Reference:
Kuehn BM. Gabapentin Increasingly Implicated in Overdose Deaths. JAMA. 2022;327(24):2387. doi:10.1001/jama.2022.10100
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751